All In MedTech

Device Trial Radar · NCT04274647

Skin Sensitization Test (Modified Draize-95 Test)

Skin Sensitization Test (Modified Draize-95) to Support a Low Dermatitis Potential Claim

Last checked: Nov 21, 2026Latest source record: Feb 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

208

Actual

Start

Sep 10, 2019

Primary completion

Feb 4, 2020

Study completion Feb 12, 2020

Sponsor

Lead sponsor
YTY Industry (Manjung) Sdn BhdNot on our public-company list
Sponsor type
Industry
First posted
Feb 18, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Skin Sensitization Test (Modified Draize-95) to Support a Low Dermatitis Potential Claim for a Blue Non Sterile Powder Free Nitrile Examination Gloves. To evaluate whether residual chemical additives at a level that may induce type IV allergy in the unsensitized general user population are present in a finished rubber containing medical device.

Conditions

  • Skin Sensitisation

Interventions

  • NON-STERILE, POWDER FREE NITRILE EXAMINATION GLOVES, LOW DERMATITIS POTENTIAL, TESTED FOR USE WITH CHEMOTHERAPY DRUGS - BLUEDevice

    Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Irritation scored by Erythemal Scoring ScaleTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Samy

    Sitiawan, Perak, Malaysia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.